middle.news
PYC Therapeutics Advances PKD Drug Candidate with Key Safety Approval
9:07am on Monday 7th of July, 2025 AEST
•
Biotechnology
Read Story
PYC Therapeutics Advances PKD Drug Candidate with Key Safety Approval
9:07am on Monday 7th of July, 2025 AEST
Key Points
Safety Review Committee approves dose escalation to cohort 3 in healthy volunteers
Initiation of Part B dosing in Polycystic Kidney Disease patients imminent
On track for repeat dose studies in PKD patients by Q4 2025
Progression toward registrational Phase 2/3 trial for PYC-003
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE